A Phase 3 interventional study of Test Drug (JDP-205) and Active Control (Diphenhydramine) in Acute Urticaria, sponsored by JDP Therapeutics, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by JDP Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Urticaria with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Urticaria · United States.
Among the 47 studies in Urticaria with a site in United States, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 in phase 3, and was the 28th registered.
148 studies on the registry are indexed under Urticaria; 19 are open to participants now.
Browse Urticaria studies →4 of the 47 studies in Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Pfizer · Sites in United States, Bulgaria, Canada and 7 more countries
Ages 18+
Foundation For Rare Disease Research · Sites in United States
Ages 12–75 · Healthy volunteers
Columbia University · Sites in United States
Ages up to 99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 6 · Phase 4 3
First in 1976; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 262 is above the median of 51 across 104 interventional studies indexed under Urticaria.
Median enrollment 39 across the 37 interventional studies, 83 across the 10 observational. Of the 39 that completed or were terminated, 21 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 47 have an industry lead sponsor. The 10 most frequent:
JDP Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
JDP Therapeutics, Inc. has 4 studies filed under Urticaria — fewer than ten, so there is no comparison to draw.
3 of the studies in Urticaria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT06210698Foundation For Rare Disease ResearchAngioedema Biomarker Research Study | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, parallel group, randomized, double-blind, active controlled, Phase III clinical study of cetirizine injection, 10 mg/mL, compared to diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent) with acute urticaria requiring treatment.
This was a multi-center, parallel group, randomized, double-blind, active controlled, Phase III clinical trial of cetirizine injection 10 mg/mL versus diphenhydramine injection 50 mg/mL (Benadryl or generic equivalent) in approximately 256 subjects who either presented to Emergency Departments, hospitals, allergy clinics or Urgent Care Centers with acute urticaria, or developed acute urticaria following allergen challenge at an Allergy Clinic.
Patients signed an informed consent and were evaluated for eligibility for inclusion to treat. Eligible subjects were assessed for baseline characteristics, medical and surgical histories, concomitant medications and given a brief physical exam.
Subjects were then randomized, in a 1:1 ratio, to blindly receive either cetirizine 10 mg/mL injection or diphenhydramine 50 mg/mL injection.
Efficacy assessments included patient-rated severity of pruritus, physician assessments of extent of urticaria/erythema, and sedation score. Subjects remained in the treatment center for at least after the 1 hr assessment, after which they may have been discharged at the physician's discretion.
Safety was monitored through the reporting of adverse events for up to 28 days following treatments and by monitoring vital signs at planned intervals from admission into the treating facility until readiness for discharge. After 24 and 48 hrs after discharge, subjects were contacted by phone for follow-up questions regarding recurrence of symptoms, new symptoms, additional medication taken, side effects from medication taken after discharge, relapse requiring a return to treatment center, and return to normal activities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JDP-205 Injection, 10 mg/mL, 1 mL
Drug: Test Drug (JDP-205)
Diphenhydramine Injection, 50 mg/mL, 1 mL
Drug: Active Control (Diphenhydramine)
Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Also known as: QUZYTTIR
Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Also known as: Benadryl
Change of Patient Rated Pruritus Score
Change from baseline to 2 hours in patient-rated pruritus Severity score (values at 2 hours minus Baseline) Patient Pruritus Severity Score Ask the patient "How severely are your hives itching at the moment?" 0 = none 1. = mild (minimal awareness, easily tolerated) 2. = moderate (definite awareness, quite bothersome) 3. = severe (difficult to tolerate)
Time frame: 2 hr
Number of Patients Who Needed to Return to Treatment Center
Number of patients who needed to return to treatment center approximately 24 hours after discharge
Time frame: up to 24 hrs
Time to Discharge
Time spent (hours) at the treatment center
Time frame: up to 24 hours
Patient Sedation Scores
Patient Sedation Score at 2 hours Ask the patient "How drowsy do you feel at the moment?" 0 = None (Not drowsy at all) 1. = Mild (Slightly drowsy) 2. = Moderate (Quite drowsy) 3. = Severe (Extremely drowsy)
Time frame: 2 hours
| Milestone | Test Drug | Control |
|---|---|---|
| Started | 127 | 135 |
| Completed | 127 | 135 |
| Not completed | 0 | 0 |
Change from baseline to 2 hours in patient-rated pruritus Severity score (values at 2 hours minus Baseline) Patient Pruritus Severity Score Ask the patient "How severely are your hives itching at the moment?" 0 = none 1. = mild (minimal awareness, easily tolerated) 2. = moderate (definite awareness, quite bothersome) 3. = severe (difficult to tolerate)
| score on a scale | Test Drug | Control |
|---|---|---|
| Change of Patient Rated Pruritus Score | -1.61 ± 0.944 | -1.50 ± 0.984 |
Number of patients who needed to return to treatment center approximately 24 hours after discharge
| Participants | Test Drug | Control |
|---|---|---|
| Number of Patients Who Needed to Return to Treatment Center | 7 | 19 |
Time spent (hours) at the treatment center
| hours | Test Drug | Control |
|---|---|---|
| Time to Discharge | 1.71 ± 0.868 | 2.07 ± 1.112 |
Patient Sedation Score at 2 hours Ask the patient "How drowsy do you feel at the moment?" 0 = None (Not drowsy at all) 1. = Mild (Slightly drowsy) 2. = Moderate (Quite drowsy) 3. = Severe (Extremely drowsy)
| score on a scale | Test Drug | Control |
|---|---|---|
| Patient Sedation Scores | 0.46 ± 0.721 | 0.88 ± 0.955 |
Collected over 28 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Drug | 0/127 (0%) | 0/127 (0%) | 5/127 (3.9%) |
| Control | 0/135 (0%) | 1/135 (0.7%) | 18/135 (13.3%) |
| Event | Test Drug | Control |
|---|---|---|
| anaphylactic reactionImmune system disorders | 0/127 | 1/135 |
| Event | Test Drug | Control |
|---|---|---|
| DizzinessNervous system disorders | 0/127 | 6/135 |
| NauseaGastrointestinal disorders | 0/127 | 4/135 |
| Burning sensationNervous system disorders | 0/127 | 2/135 |
| PyrexiaInjury, poisoning and procedural complications | 0/127 | 2/135 |
| UrticariaSkin and subcutaneous tissue disorders | 0/127 | 2/135 |
| DysgeusiaNervous system disorders | 1/127 | 1/135 |
| ParaesthesiaNervous system disorders | 1/127 | 0/135 |
| PresyncopeNervous system disorders | 1/127 | 0/135 |
| HeadacheNervous system disorders | 1/127 | 1/135 |
| DyspepsiaGastrointestinal disorders | 1/127 | 0/135 |
| Age, Continuous(years) | Test Drug | Control | Total |
|---|---|---|---|
| Mean | 39.0 ± 16.28 | 39.2 ± 15.96 | 39.1 ± 16.08 |
| Sex: Female, Male(Participants) | Test Drug | Control | Total |
|---|---|---|---|
| Female | 77 | 88 | 165 |
| Male | 50 | 47 | 97 |
| Race (NIH/OMB)(Participants) | Test Drug | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 5 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 41 | 44 | 85 |
| White | 64 | 62 | 126 |
| More than one race | 17 | 24 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Test Drug | Control | Total |
|---|---|---|---|
| United States | 127 | 135 | 262 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Apr 2018, 13 months.
Results were first posted in Nov 2019, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
JDP Therapeutics, Inc.